Annals of Indian Academy of Neurology
LETTERS TO THE EDITOR
Year
: 2020  |  Volume : 23  |  Issue : 4  |  Page : 553--555

Why does large venous pouch thrombose after cerebral arteriovenous shunts embolization?


Jidian Sun1, Xianli Lv2,  
1 Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, China
2 Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China

Correspondence Address:
Xianli Lv
Litang Road 168, Changping, Beijing, 102218
China




How to cite this article:
Sun J, Lv X. Why does large venous pouch thrombose after cerebral arteriovenous shunts embolization?.Ann Indian Acad Neurol 2020;23:553-555


How to cite this URL:
Sun J, Lv X. Why does large venous pouch thrombose after cerebral arteriovenous shunts embolization?. Ann Indian Acad Neurol [serial online] 2020 [cited 2020 Oct 22 ];23:553-555
Available from: https://www.annalsofian.org/text.asp?2020/23/4/553/270560


Full Text



Large venous pouch thrombosis following endovascular embolization is a serious and devastating complication.[1],[2],[3] It can cause venous infarction, mass effect or thrombus growth leading to a particularly poor prognosis with high morbidity and mortality rates.[2],[3] We presented two cases of severe venous pouch thrombosis developed after AVS embolization and the mechanism of venous thrombus formation and growth was discussed. The patients consented to the procedure and these cases were approved by the ethics committee of our hospital.

 Case 1



An 18-year-old man presenting with 3-month history of chemosis of the right eye underwent Magnetic Resonance Imaging (MRI) scan, which showed an orbital AVS. Cerebral angiography revealed an intraorbital AVS with a large ophthalmic vein outflow [Figure 1]. The patient underwent coil embolization of the AVS from the arterial side successfully resulting in a reduction of the shunt flow. One month later, the patient developed proptosis of his right eye, blurred vision and pulsatile tinnitus and the residual AVS was embolized completely with Onyx. Two months later, the patient presented with proptosis of his right eye and blurred vision, and MRI scanning demonstrated thrombosis of the venous pouch. At 3-year follow-up, right proptosis and blurred vision were present. MR imaging was obtained and demonstrated a massive thrombosis of the ophthalmic vein.{Figure 1}

Case 2

A 54-year-old man who had chronic headaches underwent MRI scan examination suggested cerebral AVS. Cerebral angiography revealed a dural arteriovenous shunt with a large venous pouch fed by the right middle meningeal and left posterior auricular arteries [Figure 2]. The patient underwent complete embolization of the AVS from the right middle meningeal and left posterior auricular arteries using Onyx. On the second day, the patient developed bilateral oculomotor nerve palsy with bilateral ataxia is named Claude's syndrome. MR imaging was obtained and demonstrated a thrombosis of precentral vein and the venous pouch, brain edema. Six months after embolization, the symptoms were still persistent.{Figure 2}

 Discussion



In this report, 2 cases with massive thrombotic change of drainers after embolization were introduced. Such complications are well-known but expansive thrombosed varix like as these cases may be very rare. In the two cases presented by Gonzalez et al.,[1] venous thrombus after treatment of fistula resulted in significant complications. In series on 30 patients with dural AVS treated with Onyx embolization and strict anticoagulation, Cognard et al.[4] reported one case of extensive thrombus of the draining vein with cerebellar bleeding following successful obliteration of the shunt. In another large series that included 121 dural AVS treated with transarterial glue embolization, Kim et al.[5] noted some degree of venous thrombus in the postoperative period in 5 patients. One of these patients recovered spontaneously, while the other patients were treated with anticoagulant or steroid therapy. As the authors indicate, the use of anticoagulation may be one way to reduce the risk of this complication. As this complication is rare, it remains unclear which patients should be anticoagulated.

Venous thrombus forming under lower shear stress on the surface of a largely intact endothelium are fibrin-rich (so called “red clots” because they also contain red blood cells) and are treated with anticoagulant drugs.[6],[7],[8],[9] Rivaroxaban was shown to be superior to the low-molecular-weight heparin enoxaparin in reducing venous thrombosis embolization in four clinical trials involving total knee and hip replacement.[10] Reduced hemodynamics or vascular wall pathology allows the accumulation of procoagulant proteases, such as thrombin, that may induce thrombosis. One may propose that the first step in venous thrombosis is activation of the endothelium and expression of the adhesion receptors P-selectin and E-selectin as well as von Willebrand factor (vWF). The activated endothelium then captures circulating leukocytes, tissue factor (TF) positive monocyte-derived microvesicles (MVs), and platelets. Finally, induction of TF expressed by the bound leukocytes together with TF on MVs triggers thrombosis.

 Conclusions



Changes in blood flow in the blood itself and in the endothelium all increase the risk of venous thrombosis embolization. Leukocytes, platelets and MVs in the initiation and propagation of the thrombus and suggest that inhibition of the binding of leukocytes and MVs to the activated endothelium may represent a new therapeutic strategy to reduce the risk of venous thrombosis embolization.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

This work was funded by National Natural Science Foundation of China (grant No. 81371314) and The National Key Research and Development Program of China (2016YFC1301800).

Conflicts of interest

There are no conflicts of interest.

References

1Gonzalez LF, Chalouhi N, Jabbour P, Teufack S, Albuquerque FC, Spetzler RF. Rapid and progressive venous Thrombus after occlusion of high-flow arteriovenous fistula. World Neurosurg 2013;80:e359-65.
2Jiang C, Lv X, Wu Z. Clinical-pathology review: Supratentorial cerebral arteriovenous fistula. Eur J Radiol Extra 2009;72:e97-102
3Lv X, Jiang C, Li Y, Yang X, Wu Z. Clinical outcomes of endovascular treatment for intracranial pial arteriovenous fistulas. World Neurosurg 2010; 73:385-90.
4Cognard C, Januel AC, Silva NA Jr, Tall P. Endovascular treatment of intracranial dural arteriovenous fistulas with cortical venous drainage: New management using Onyx. AJNR Am J Neuroradiol 2008;29:235-41.
5Kim DJ, Willinsky RA, Krings T, Agid R, Terbrugge K. Intracranial dural arteriovenous shunts: Transarterial glue embolization—experience in 115 consecutive patients. Radiology 2011;258:554-61.
6Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008;28:387-91.
7Undas A, Ariëns RA. Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011;31:e88-99.
8Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure, and stability. Haemophilia 2010;16(Suppl 3):7-12.
9Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004;24:1015-22.
10Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444-53.